Global Fund releases mid-year results for HIV, TB, malaria

NewsGuard 100/100 Score
Jun 10 2010

The Global Fund to Fight AIDS, Tuberculosis and Malaria announced mid-year results for HIV and TB treatment as well as for insecticide-treated net (ITN) distribution, Sify News reports. According to the report, by mid-2010 Global Fund-financed programs have:

  • Provided antiretrovirals to 2.8 million people with HIV/AIDS, a 22% increase over mid-2009;
  • Treated 7 million people for tuberculosis, a 30% increase over mid-2009; and
  • Distributed 122 million ITNs to prevent malaria infection, a 39% increase over mid-2009 (6/9).

Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Posted in: Disease/Infection News

Tags: , , , , ,

Comments (0)

Suggested Reading

Study reveals increased risk of immune abnormalities in children of women with HIV
Unveiling the key role of RNA modification in HIV-1 survival and replication
Global HIV epidemic cannot be ended without keeping former prisoners, other patients engaged in care
Common HIV drugs linked to reduced Alzheimer's disease risk
Oxford University and Brazil partner to advance malaria vaccine development
Sugar abnormalities in the blood may promote biological aging and inflammation in HIV patients
New report on HIV drug resistance: Challenges and recommendations
Innovative malaria prodrug targets liver, enhances efficacy while reducing toxicity, preclinical studies show

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
New malaria vaccine strain shows promise in preclinical trials